New hope for aggressive lung cancer: major trial launches
NCT ID NCT07502300
Summary
This large Phase 3 trial will compare a new experimental drug, BL-B01D1, combined with an immunotherapy (tislelizumab) against the current standard platinum-based chemotherapy combined with the same immunotherapy. It aims to see if the new combination helps people with extensive-stage small cell lung cancer live longer and control their disease better. The study will enroll 562 adults who have not yet received any systemic treatment for this aggressive form of cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.